Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights
Emrosi™ approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; initial distribution ...
Adcendo Aps Announces Changes In Board Of Directors And Strengthens Executive Leadership Team
Healthcare pioneer Laura Shawver, Ph.D. appointed Chair of the Board and industry veteran Roy Baynes M.D., Ph.D. appointed as independent, non-exe ...
Psychology Today1d
Study Finds AI Chatbot Can Improve Mental Health
Study finds AI chatbot significantly improve symptoms for those suffering from major depressive disorder (MDD), generalized ...
Gain Therapeutics, Inc.: Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update
Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the ...
Fierce Biotech4d
'It's just ugly': Federal funding cuts to Columbia University leave chronic fatigue syndrome research in limbo
Earlier this month, Ian Lipkin, M.D., and his team at Columbia University submitted a paper for publication that suggests ...
Le Lézard4d
Adams Clinical Announces Appointment of Dr. Colin Sauder as Chief Scientific Officer and Expansion of Clinical Team to Support Strategic Growth
Adams Clinical Site Network ("Adams", or the "Company"), a leading Neuroscience-focused clinical trial site network announced today that Dr. Colin Sauder, PhD has joined the company as Chief ...
Johns Hopkins Medicine1d
Experimental Blood Test Shown to Accurately Indicate Severity and Predict Potential Recovery From Spinal Cord Injury
New study in @jclinicalinvest by @HopkinsMedicine researchers suggests experimental blood test can indicate spinal cord ...
Mirage News1d
Blood Test Predicts Severity, Recovery in Spinal Injuries
By analyzing DNA and proteins in the blood of people with and without acute spinal cord injuries (SCIs), researchers at the ...
Yahoo Finance4d
3 Reasons Investors Watch United Therapeutics (UTHR)
3 Reasons Investors Watch United Therapeutics (UTHR) Over the last six months, United Therapeutics shares have sunk to $308.27, producing a disappointing 14% loss - worse than the S&P 500’s 1.4% ...
Yahoo Finance4d
United Therapeutics (UTHR) Down 4.8% Since Last Earnings Report: Can It Rebound?
A month has gone by since the last earnings report for United Therapeutics (UTHR). Shares have lost about 4.8% in that time frame, underperforming the S&P 500. Will the recent negative trend ...